needed effects
simeprevir
active ingredient
olysio
unwanted side effects
medical attention
simeprevir side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
clinical trials
most side effects
weeks therapy with this drug in combination with peginterferon alfa
ribavirin
grade
severity
grade
side effects
subjects
drug with peginterferon alfa
ribavirin
using placebo with peginterferon alfa
ribavirin
serious side effects
subjects
drug with peginterferon alfa
ribavirin
using placebo with peginterferon alfa
ribavirin
first weeks of therapy
common side effects
nausea
rash
pruritus
dyspnea
increased blood bilirubin
photosensitivity reaction
drug
side effects
subjects
drug with peginterferon alfa
ribavirin
clinical trial
common side effects
weeks therapy with this drug in combination with sofosbuvir
ribavirin
fatigue
headache
nausea
insomnia
pruritus
manufacturer product information for coadministered hepatitis c virus
hcv
antiviral drugs
grade
hyperbilirubinemia
patients
bilirubin elevations
severity
elevation of both direct
indirect bilirubin
bilirubin elevations
therapy
second week
drug
bilirubin elevations
liver transaminase elevations
incidence
increased bilirubin
patients
increased simeprevir
active ingredient
olysio
exposures
pooled phase population from global trials
east asian patients
drug with peginterferon alfa
ribavirin
higher incidence of hyperbilirubinemia
elevated total bilirubin
grades
patients
bilirubin elevations
grade
grade bilirubin elevations
patients
bilirubin elevations
liver transaminase elevations
therapy
increased bilirubin
patients
drug with sofosbuvir
using
drug with sofosbuvir
ribavirin
hepatic decompensation
hepatic failure
including fatalities
drug
peginterferon alfa
ribavirin
sofosbuvir
most reports
patients with advanced
decompensated cirrhosis
increased blood bilirubin
term
conjugated bilirubin
increased blood bilirubin
unconjugated blood bilirubin
hyperbilirubinemia
postmarketing reports
hepatic decompensation
hepatic failure
percent of rash events
first weeks
first weeks
most rash
pruritus events
moderate severity
severe rash
subjects
drug
rash
subjects
frequencies of rash
photosensitivity reactions
subjects with higher simeprevir
active ingredient
olysio
exposures
rash
patients
drug with sofosbuvir
ribavirin
using
drug with sofosbuvir
pruritus
patients
drug with sofosbuvir
trial subjects
sun protection measures
most photosensitivity reactions
moderate severity
subjects
photosensitivity reactions
hospitalization
photosensitivity reactions
patients
drug with sofosbuvir
using
drug with sofosbuvir
ribavirin
rash
including photosensitivity
term
rash
erythema
eczema
maculopapular rash
macular rash
dermatitis
papular rash
skin exfoliation
pruritic rash
erythematous rash
urticaria
generalized rash
drug eruption
allergic dermatitis
dermatosis
vasculitic rash
toxic skin eruption
exfoliative rash
generalized erythema
exfoliative dermatitis
cutaneous vasculitis
photosensitivity reaction
polymorphic light eruption
solar dermatitis
photodermatosis
sunburn
blister
macule
erythema of eyelid
palmar erythema
papule
pityriasis rosea
follicular rash
morbilliform rash
pustular rash
scrotal erythema
skin irritation
skin reaction
umbilical erythema
pruritus
term
pruritus
generalized pruritus
eyelids pruritus
prurigo
photosensitivity reaction
fatigue
patients
drug with sofosbuvir
fatigue
nausea
diarrhea
constipation
nausea
patients
drug with sofosbuvir
diarrhea
weeks therapy with this drug
sofosbuvir
headache
dizziness
headache
patients
drug with sofosbuvir
dizziness
weeks therapy with this drug
sofosbuvir
myalgia
insomnia
patients
drug with sofosbuvir
insomnia
anemia
patients
drug with sofosbuvir
ribavirin
using
drug with sofosbuvir
higher incidence of anemia
patients with advanced fibrosis
anemia
dyspnea
term
dyspnea
exertional dyspnea
dyspnea events
moderate severity
percent of dyspnea events
first weeks
patients
years
dyspnea
patients
drug
using placebo with peginterferon alfa
ribavirin
grade
alkaline phosphatase elevations
patients
increased alkaline phosphatase
postmarketing reports
symptomatic bradycardia
including cases
requiring pacemaker intervention
serious symptomatic bradycardia
patients
taking amiodarone
therapy with sofosbuvir in combination with another hcv
including
drug
side effects of olysio
fda
healthcare professional for medical advice
blistering
crusting
irritation
itching
reddening of the skin
scaly skin
breathing
increased sensitivity of the skin
sunlight
rash with flat lesions
small raised lesions on the skin
rash, itching skin
redness
other discoloration of the skin
severe sunburn
tightness in the chest
difficulty with moving
joint pain
muscle
cramping
muscle pains
stiffness
nausea
swollen joints